interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Acoramidis Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Acoramidis Hydrochloride, and who makes it?

Acoramidis Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Acoramidis Hydrochloride1 dosage-form group in the Orange Book
0generic makers listed
  1. Acoramidis Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Attruby. No generic is listed as marketed.

2020202520302035204001brand 2024data datePatent 9169214 listed to expire 5 May 2031Patent 9913826 listed to expire 5 May 2031Patent 10842777 listed to expire 5 May 2031Patent 10398681 listed to expire 5 May 2031Patent 9642838 listed to expire 5 May 2031Patent 8877795 listed to expire 5 May 2031Patent 11919865 listed to expire 16 February 2038Patent 10513497 listed to expire 16 February 2038Patent 11058668 listed to expire 22 March 2039Patent 12070449 listed to expire 22 March 2039Patent 12005043 listed to expire 16 August 2039Patent 12539290 listed to expire 16 August 2039Patent 11260047 listed to expire 16 August 2039Exclusivity NCE to 22 November 2029Exclusivity ODE-506 to 22 November 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 November 2029Exclusivity NCE Attruby
  • 22 November 2031Exclusivity ODE-506 Attruby
  • 5 May 2031Patent 9169214 drug product
  • 5 May 2031Patent 9913826
  • 5 May 2031Patent 10842777
  • 5 May 2031Patent 10398681 drug product
  • 5 May 2031Patent 9642838 drug substance
  • 5 May 2031Patent 8877795 drug product
  • 16 February 2038Patent 11919865
  • 16 February 2038Patent 10513497 drug substance

5 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.